Search Results
Your search for ,USE matches 11257 pages
Showing 3551 - 3600How Did the COVID-19 Pandemic Affect Initiation of Cancer Treatment in England?
In a retrospective analysis reported in The Lancet Oncology, Clark et al found that new prescriptions for systemic anticancer treatment in England initially declined significantly after societal lockdown in response to the COVID-19 pandemic. However, they then increased to higher than prepandemic...
Assessing the Progress Made in Global Cancer Care and Looking Toward the Future
In October 2020, Her Royal Highness Princess Dina Mired of Jordan ended her 2-year tenure as President of the Union for International Cancer Control (UICC), a global organization with more than 1,198 members from 172 countries and territories committed to reducing the cancer burden and...
Proportion of Never-Smokers Among Patients With Lung Cancer in Seven U.S. States
In a study reported in a research letter in JAMA Oncology, Siegel et al found that never-smokers accounted for 12.5% of patients diagnosed with lung cancer in seven U.S. states during a recent 6-year period, with women accounting for a higher proportion than men. Study Details The study included...
ASH 2020: Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic Phase CML
Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosutinib, and ponatinib. These drugs attack a similar target, making it more likely that resistance to...
ASH 2020: Early Research Shows CD58 May Be a Biomarker for Response to Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma
Although the immunotherapy axicabtagene ciloleucel has significantly improved treatment outcomes for some patients with large B-cell lymphoma, not all patients benefit. In a new study presented by Robbie G. Majzner, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting ...
ASH 2020: APOLLO Findings Support Use of Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma
For patients with relapsed or refractory multiple myeloma whose disease progressed after at least one prior regimen, the subcutaneous form of daratumumab, given with pomalidomide and dexamethasone, significantly improved progression-free survival vs pomalidomide and low-dose dexamethasone alone....
ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies
The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophylactic platelet transfusions, according to findings presented by Terry B. Gernsheimer, MD, and...
ASH 2020: Does Race Contribute to Poor Outcomes in Younger Black Patients Diagnosed With AML?
It has been well documented that, collectively, Black individuals have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also have the highest cancer incidence. Although the causes of these inequities are complex, a study by...
Statins Reduced Risk of Colorectal Cancer in Meta-analysis
A systematic meta-analysis has shown that statin users had a significantly reduced risk of colorectal cancer. The study included patients with and without inflammatory bowel disease, which is associated with an increased risk of this type of cancer. The largest chemopreventive effect was observed...
Study Shows Regional Variation in Genomic Testing for Men With Prostate Cancer
A study published by Michael S. Leapman, MD, and colleagues in JAMA Oncology found substantial regional variation in the use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies. “Little was known...
Association of Fall and Fracture Risk With Androgen Receptor Inhibitor Therapy for Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Myint et al found that androgen receptor inhibitor therapy for prostate cancer was associated with an increased risk of both falls and fractures. Study Details The meta-analysis included 11 randomized trials reported through...
Expert Point of View: Brooks D. Cash, MD
Brooks D. Cash, MD, Chief of Gastroenterology, Hepatology & Nutrition at McGovern Medical School at UTHealth in Houston, moderated the plenary session during the virtual edition of the American College of Gastroenterology 2020 Annual Scientific Meeting, where the data were presented. He...
Managing Checkpoint Inhibitor–Mediated Colitis: Vedolizumab vs Infliximab
For patients who develop severe diarrhea or colitis while receiving checkpoint inhibitors, the immunosuppressive agent vedolizumab is preferred over infliximab, according to an expert on the topic from The University of Texas MD Anderson Cancer Center. A retrospective comparison of outcomes with...
FDA Approves Gallium-68 PSMA-11 for PSMA-Targeted PET Imaging in Prostate Cancer
On December 1, the U.S. Food and Drug Administration (FDA) approved gallium-68 PSMA-11—the first drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Gallium-68 PSMA-11 is indicated for patients with suspected ...
Does Concurrent Treatment With Dexamethasone Diminish the Efficacy of Immune Checkpoint Inhibitors in Patients With Glioblastoma?
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published by Iorgulescu et al in Clinical Cancer Research....
FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for December 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc. “In keeping with the FDA’s commitment ...
Trends in Positive BRCA Test Results Among Women Aged 65 and Older in the United States
In a study reported in JAMA Network Open, Guo et al found that the proportion of positive BRCA genetic test results markedly declined between 2008 and 2018 among women aged ≥ 65 years in the United States, with the trend likely reflecting what the investigators call a loosening of testing criteria...
ESMO Asia 2020: Performance of Immunoscore in Asian Patients With Early-Stage Colon Cancer
The Immunoscore assay can assess the risk of disease recurrence in Asian patients with early-stage colon cancer and may be used together with TNM classification to guide clinical decision-making, according to findings presented at the European Society for Medical Oncology (ESMO) Asia Virtual...
No Reduction in Recurrence Risk With Perioperative Aromatase Inhibitor Therapy in Postmenopausal Patients With HR-Positive Breast Cancer
As reported in The Lancet Oncology by Ian E. Smith, MD, and colleagues, the phase III POETIC trial found that perioperative aromatase inhibitor therapy did not reduce the risk of disease recurrence in postmenopausal women with hormone receptor (HR)-positive early breast cancer vs no perioperative...
Effect of Fertility Preservation on Reproductive Outcomes in Patients After Breast Cancer
In a Swedish nationwide cohort study reported in JAMA Oncology, Marklund et al found that women who had undergone fertility preservation had a higher live birth rate, were more likely to use assisted reproductive technology, and had better overall survival after breast cancer than women who had not ...
Case Series Study Explores Experiences of Transgender Patients With Cancer
In a retrospective case series reported in JAMA Oncology, Burns et al described clinical characteristics, treatment, experiences, and outcomes among transgender patients with cancer. As stated by the investigators, “Approximately 0.5% to 0.6% of the U.S. population identify as transgender, defined...
New Global Survey Finds More Education Needed to Increase Provider Geriatric Assessments for Older Adults With Cancer
Oncology providers familiar with ASCO’s guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are...
Rogel Team at University of Michigan Receives $11.2M to Leverage the Microbiome Against Graft-vs-Host Disease
A team of researchers from the University of Michigan Rogel Cancer Center in Ann Arbor received an $11.2 million grant from the National Heart, Lung, and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases....
Mohs Surgery vs Wide Local Excision for Trunk and Extremity Melanomas: Comparable Overall Survival Rates
A cohort study of 188,862 cases of all-stage melanomas of the trunk and extremities found no differences in overall survival between patients treated with Mohs micrographic surgery or with wide local excision.1 “These findings add to the existing body of evidence demonstrating that wide local...
SIO and ASCO Collaborate to Develop Evidence-Based Guidelines for Integrative Therapies for Oncology
The Society for Integrative Oncology (SIO) has announced its collaboration with ASCO in the development of a series of evidence-based clinical practice guidelines for integrative therapies in oncology care. The guidelines, planned for publication in 2021 and 2022, will provide clinicians and...
Darolutamide Improves Overall Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: ARAMIS Trial
As reported in The New England Journal of Medicine by Karim Fizazi, MD, of the Institut Gustave Roussy, University of Paris-Saclay, Villejuif, and colleagues, the phase III ARAMIS trial has shown significantly prolonged overall survival with darolutamide vs placebo in men with nonmetastatic...
ACS Cancer Action Network Issues New Recommendations to Increase Access to Cancer Biomarker Testing
The American Cancer Society (ACS) Cancer Action Network has released new policy recommendations to increase the uptake of biomarker testing and to advance the use of precision medicine in cancer care. A recent report by the ACS Cancer Action Network and the LUNGevity Foundation found that although...
Racial Disparities in Treatment of Common Lung Cancer Persist Despite Gains
Lung cancer continues to be the most deadly solid cancer in the world, despite the fact that survival rates have been improving over the past decade. However, Black patients have worse outcomes and shorter lifespans after being diagnosed with lung cancer. A study published in the Journal of...
UT Austin and MD Anderson Announce First Collaborative Projects in Improving Cancer Outcomes
The University of Texas (UT) MD Anderson Cancer Center, UT Austin Oden Institute for Computational Engineering and Sciences, and UT Austin Texas Advanced Computing Center (TACC) launched a new collaboration in oncologic data and computational science earlier this year. The strategic initiative...
Understanding the Uniqueness of Cancer and Survival in Adolescents and Young Adults
Numerous studies over the past 4 decades have chronicled the lack of progress in improved outcomes for adolescents and young adults (AYAs)—defined by the National Cancer Institute as those ranging in age from 15 to 39—diagnosed with cancer compared with children and older adults diagnosed with the...
Venetoclax in Combination Therapy for Untreated Acute Myeloid Leukemia
On October 16, 2020, venetoclax was granted regular approval for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or those with comorbidities precluding intensive induction...
Update on Multiple Myeloma: Highlights From NCCN Virtual Congress on Hematologic Malignancies
New diagnostic criteria and modern imaging techniques, a wealth of new therapeutics, and an update on current thinking as to when to treat patients with smoldering myeloma were highlighted during the National Comprehensive Cancer Network (NCCN) 2020 Virtual Congress: Hematologic Malignancies™....
A Urologic Surgeon Assesses the Current State of Prostate Cancer
Despite decades of research, multinational clinical trials, regular guideline updates by the U.S. Preventive Services Task Force, and coordinated efforts by ASCO and other major oncology organizations, the management strategy for prostate cancer remains controversial. To keep the oncology community ...
This Year’s FDA-ASCO Workshop Focused on Collection of Patient-Reported Tolerability Data From Clinical Trials
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Vishal Bhatnagar, MD, Associate Director for Patient Outcomes, Bellinda King-Kallimanis, PhD, Senior Staff...
Support Builds for Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Based on early results in clinical trials, interest in the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma has been high, especially for products targeting B-cell maturation antigen (BCMA). During the ASCO20 Virtual Scientific Program, further support for CAR T-cell...
Expert Point of View: Fatima Cardoso, MD
The SOLAR-1 invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud Clinical Center in Lisbon and Chair of the ABC Global Alliance, commented: “The overall survival results, though numerically different by almost 8 months, unfortunately do not reach statistical...
Final Analysis of SOLAR-1: 8-Month Survival Benefit Misses Statistical Significance for Alpelisib
The statistically significant benefit of alpelisib in reducing disease progression, as reported at the European Society for Medical Oncology (ESMO) Congress 2 years ago, did not translate into a significant improvement in overall survival, although a numerical 8-month gain was observed in the final ...
Growing Interest in Antiandrogens to Treat Male Breast Cancer
“There has been a lot of interest in the development of new antiandrogens” for clinical use in patients with breast cancer,” Anthony D. Elias, MD, reported in an update on male breast cancer at the 2020 Lynn Sage Breast Cancer Symposium, sponsored by the Robert H. Lurie Comprehensive Cancer Center...
Pembrolizumab in Adult and Pediatric Classical Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 14, 2020, the approval of pembrolizumab was...
MINDACT at 8.7 Years: Primary Findings Confirmed
Long-term analysis of the phase III MINDACT trial, with a median follow-up of 8.7 years, confirmed that the 70-gene signature MammaPrint assay can identify which patients with breast cancer can safely forgo adjuvant chemotherapy, reported Emiel Rutgers, MD, PhD, FRCS, a surgical oncologist at the...
Expert Point of View: Emiliano Calvo, MD, and Udai Banerji, MD
Press briefing moderator and meeting Co-Chair, Emiliano Calvo, MD, Director of the START Madrid Group and Director of Clinical Research at the START Madrid-Centro Integral Oncologico Clara Campal Hospital, stated: “Using drugs that are already approved and in worldwide use, and to be able to...
Daniel Sullivan, MD, Honored for Leadership in Quantitative Imaging Biomarkers
The Prevent Cancer Foundation recently honored Daniel C. Sullivan, MD, with the James L. Mulshine, MD Leadership Award for his work in founding and chairing the Quantitative Imaging Biomarkers Alliance (QIBA). The Quantitative Imaging Biomarkers Alliance is committed to attempting to transform...
Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158
The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual edition of the International Association for the Study of Lung Cancer (IASLC) 2020 North America...
Nagi S. El Saghir, MD, FACP, FASCO, Receives Lebanon’s National Cedar Medal Award
One of Lebanon’s highest national awards, the National Cedar Medal (Commander Rank), was recently bestowed upon Nagi S. El Saghir, MD, FACP, FASCO, in recognition of his extensive contributions to the fields of medicine, education, and science—and most particularly, for his efforts in the fight...
Image-Guided IMRT Reduces GI Toxicity Without Compromising Pelvic Recurrence in Intermediate- to High-Risk Cervical Cancer
Post-hysterectomy image-guided intensity-modulated radiation therapy (IMRT) was superior to three-dimensional conformal radiation therapy (3D-CRT) in reducing the side effects of pelvic radiation while achieving similar tumor control in women with high-risk cervical cancer, according to the final...
Impact of COVID-19 on Cancer Care in India
With the announcement of a complete nationwide lockdown on March 25, 2020, to prevent the spread of COVID-19, a lot of unprecedented events came into being in India. The National Health Mission reported a 69% reduction in measles, mumps, and rubella vaccination in children; a 21% reduction in...
Phase II Study Investigates Efficacy of Anlotinib in Radioiodine-Refractory Differentiated Thyroid Cancer
Patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma demonstrated a statistically significant progression-free survival benefit when treated with anlotinib, a novel tyrosine kinase inhibitor, vs placebo, as well as higher response rates, according to...
Fluciclovine PET Imaging Benefits Radiotherapy Treatment Planning Compared With Conventional Imaging in Prostate Cancer
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for radiotherapy treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic ...
Reconstruction Implant Surface Texture and Risk of Breast Cancer Recurrence
In a Korean single-institution cohort study reported in JAMA Surgery, Lee et al found that the use of textured surface implants in breast reconstruction following mastectomy for breast cancer was associated with poorer disease-free survival. Study Details The study involved data from 650 women...
Adoption of Hypofractionated Radiation Therapy After Change in Prostate Cancer Clinical Pathway
In a study reported in JCO Oncology Practice, Schad et al found that modifying the prostate cancer clinical pathway in an integrated oncology network to designate moderately hypofractionated external-beam radiotherapy (mHF-EBRT) as the recommended curative EBRT monotherapy in low- and...
